Search Results
Your search for ,WHo matches 20199 pages
Showing 14601 - 14650Ibrutinib in Relapsed Mantle Cell Lymphoma
Treatment of mantle cell lymphoma continues to evolve, both in the front-line and relapsed settings. Key advances include better use of established agents, such as the incorporation of high-dose cytarabine into initial induction regimens and application of rituximab (Rituxan)...
Phase III Trial Shows Improved Progression-Free Survival With Ibrutinib vs Temsirolimus in Relapsed/Refractory Mantle Cell Lymphoma
In aphase III trial reported in The Lancet and at the recent American Society of Hematology Annual Meeting and Exposition, Martin Dreyling, MD, of the European Mantle Cell Lymphoma Network, and colleagues found that ibrutinib (Imbruvica) was associated with improved progression-free survival vs...
New Society of Breast Imaging Website Seeks to End Confusion Surrounding Mammography Screening
Breast cancer is the second-leading cause of cancer deaths among women in the United States. In 2015, according to the National Cancer Institute, 231,840 women were to be diagnosed with the disease and 40,290 were to die from it. The death rate is highest among women who are not screened regularly...
Winning the Battle at the Front Lines: Lenalidomide Plus Rituximab— A Promising Initial Treatment for Mantle Cell Lymphoma
Mantle cell lymphoma is a pernicious, incurable disease. Front-line therapies for this disease are not currently standardized; however, novel therapies for relapsed or refractory mantle cell lymphoma can ideally be translated into beneficial treatments for newly diagnosed patients, as clearly...
Lenalidomide Plus Rituximab Highly Active in Initial Treatment of Mantle Cell Lymphoma
In a phase II trial reported in The New England Journal of Medicine by Jia Ruan, MD, PhD, and colleagues, first-line treatment with the immunomodulatory agent lenalidomide (Revlimid) and the anti-CD20 antibody rituximab (Rituxan) followed by maintenance lenalidomide and rituximab produced a high...
Terence S. Dermody, MD, Named Chair of Pediatrics at UPMC and Scientific Director of Children’s Hospital of Pittsburgh
Terence S. Dermody, MD, has been named the Chair of the Department of Pediatrics at the University of Pittsburgh School of Medicine and Physician-in-Chief and Scientific Director at Children’s Hospital of Pittsburgh of the University of Pittsburgh Medical Center (UPMC). Dr. Dermody will officially...
Community Oncology Alliance Elects New Officers and Board Members for 2016
The Community Oncology Alliance (COA), a nonprofit organization dedicated to advocating for community oncology practices and the patients they serve, announced the election of a new Board of Directors and Executive Committee officers. “2016 is primed to be an important year for community oncology....
The New Frontiers of Breast Cancer
A seismic shift is underway in screening and treatment approaches for breast cancer. These changes are being fueled by studies showing that mammography in younger women may do more harm than good and that advances in genomic testing and a better understanding of the biology of breast cancers may...
How Effective Communication Can Improve Patient Care—and Reduce Physician Burnout
Surveys conducted between 1950 and 1970 show that most physicians considered it inhumane to give patients with a poor cancer prognosis the bad news.1,2 Since then, it has been well established that open communication between physician and patient is an essential part of effective cancer care and...
The Evolving Treatment Landscape of ALK-Positive NSCLC
Since the initial discovery of ALK rearrangement in non–small cell lung cancer (NSCLC) in 2007,1 small molecule tyrosine kinase inhibitors of ALK have transformed the course of disease for those patients with ALK-rearranged (ie, ALK-positive) NSCLC. Crizotinib (Xalkori), a multitargeted tyrosine...
International Innovation Grant Supports Novel Breast Cancer Health Education Program in Mexico
The International Innovation Grant, funded by the Conquer Cancer Foundation (CCF) of ASCO, provides research funding in support of novel and innovative projects that can have a significant impact on cancer control in low- and middle-income countries. The grant is intended to support research that...
Conquer Cancer Foundation Hosts Inaugural Scientific and Career Development Retreat
In October 2015, the Conquer Cancer Foundation of ASCO (CCF) hosted its first Scientific and Career Development Retreat at ASCO Headquarters in Alexandria, Virginia, for past recipients of the Young Investigator Award (YIA) and Career Development Award (CDA). The YIA provides funding to promising...
Global and North American Phase II Studies Show Alectinib Is Highly Active in Crizotinib-Resistant/Refractory ALK-Rearranged NSCLC
In two phase II trials, reported in the Journal of Clinical Oncology and The Lancet Oncology, the ALK inhibitor alectinib (Alecensa), which is active against acquired crizotinib resistance mutations and exhibits high central nervous system (CNS) penetration, was associated with considerable...
Blood Test Can Predict High-Risk Cancers in Patients Treated With CAR-T
Dramatic advances have been made in using genetically engineered chimeric antigen receptor–modified T cells (CAR-T) with anti-CD19 specificity to treat highly refractory hematologic malignancies. The highest complete remission rates have been achieved in patients with relapsed or refractory acute...
Expert Point of View: Sagar Lonial, MD
Responding to the assertion that bortezomib (Velcade)/lenalidomide (Revlimid)/low-dose dexamethasone induction followed by continuous lenalidomide/dexamethasone is potentially a new standard of care in newly diagnosed multiple myeloma, Sagar Lonial, MD, Chief Medical Officer of Winship Cancer...
I Am Not Afraid of Cancer
At age 73, I’m no shrinking violet and I don’t run to the doctor at the first sign of a problem. I practice naturopathy and can usually ward off potential health issues by maintaining a healthy diet and lifestyle. When I began experiencing some mild discomfort in my rectum 2½ years ago, I was...
Computerized Cognitive Training Promising for Reducing Cognitive Late Effects in Childhood Cancer Survivors
In a study reported in the Journal of Clinical Oncology, Heather M. Conklin, PhD, of St. Jude Children’s Research Hospital, and colleagues found that computerized cognitive training showed promise in reducing cognitive late effects in survivors of childhood cancer.1 Study Details In the study,...
Exploratory Analysis of ExteNET Trial Shows Consistency of Benefit With Neratinib
An exploratory analysis of the ExteNET study of neratinib in early HER2-positive breast cancer after treatment with trastuzumab (Herceptin) upheld the findings previously reported for the 2-year analysis, according to the study’s principal investigator Arlene Chan, MD, of the Breast Cancer...
Expert Point of View: George Sledge, MD
George Sledge, MD, Professor, and Chief, Division of Oncology, Stanford University Medical Center, told The ASCO Post that he found the data from the pooled analysis “very exciting.” “One of the big questions in triple-negative breast cancer is how to select which drugs work best for which...
Homologous Recombination Deficiency Score Correlated With Response to Platinum in Breast Cancer
The homologous recombination deficiency (HRD) score may be a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple-negative breast cancer, according to studies presented at the 2015 San Antonio Breast Cancer Symposium. “We found, in our adjusted analysis,...
Pancreas Cancer Liquid Biopsy: Proof-of-Principle Study
Pancreatic cancer tumors are ripe for analysis with a liquid biopsy, according to researchers at The University of Texas MD Anderson Cancer Center. In a proof-of-principle study published recently in Annals of Oncology,1 the investigators reported on research in which they conducted whole-genome,...
Uridine Triacetate Granules for Fluorouracil or Capecitabine Overdose or Early Severe Toxicity
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 11, 2015, uridine triacetate (Vistogard) was approved...
Expert Point of View: Angela DeMichele, MD, and Melinda L. Telli, MD
The formal discussant for the CALGB 40603 and GeparSixto studies at the San Antonio Breast Cancer Symposium was Angela DeMichele, MD, Professor of Medicine and Miller Chair in Breast Cancer Excellence at the Perelman School of Medicine, University of Pennyslvania. “The key questions raised by these ...
Role of Carboplatin in Triple-Negative Breast Cancer Still Unclear
Studies presented at the 2015 San Antonio Breast Cancer Symposium built upon an increasing body of data in support of the neoadjuvant use of carboplatin in patients with triple-negative breast cancer. Overall, however, the studies fell short of establishing carboplatin’s role in this malignancy and ...
Immunotherapy for Breast Cancer: Early Lackluster Study Results yet Promise Remains
Immunotherapy is at the forefront of exciting new approaches to cancer, with excellent and long-lasting responses in metastatic melanoma and non–small cell lung cancer (NSCLC) and several immunotherapy agents now approved for those malignancies by the U.S. Food and Drug Administration (FDA). The...
Sally Vernon, PhD, Appointed to National Cancer Institute Board
Sally Vernon, PhD, Chair of the Department of Health Promotion and Behavioral Sciences at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, has been appointed to the Board of Scientific Counselors for Clinical Sciences and Epidemiology at the National...
Expert Point of View: Kevin S. Hughes, MD
This study confirms that what is important is a negative margin, not the margin size,” said Kevin S. Hughes, MD, a breast surgeon who is Co-Director of the Avon Comprehensive Breast Evaluation Center at Massachusetts General Hospital, Boston. “This is a confirmatory study of the consensus...
Surgical Margin Width Not Related to Breast Cancer Recurrence
The width of the surgical margin doesn’t matter, as long as the margin is negative, according to a large study of breast-conserving surgery in patients with invasive breast cancer. The risk of ipsilateral breast tumor recurrence was similar for wide negative margins (2–4 mm) or narrow negative...
Expert Point of View: Carlos L. Arteaga, MD
Carlos L. Arteaga, MD, the Donna S. Hall Chair in Breast Cancer Research and Director of the Center for Cancer Targeted Therapies at Vanderbilt University School of Medicine, Nashville, commented on the BELLE-2 trial for The ASCO Post. “We have learned that there is a subgroup of patients, who are...
PI3K Inhibitor Buparlisib Extends Progression-Free Survival in Advanced Breast Cancer
Addition of the oral investigational pan-PI3K inhibitor buparlisib to the endocrine agent fulvestrant (Faslodex) improved progression-free survival among postmenopausal women with advanced hormone receptor–positive/HER2-negative advanced breast cancer. “We are happy to announce that the phase III...
Study Finds Colorectal Cancer More Likely to Affect Minorities at Younger Age
Researchers at the University of Missouri School of Medicine reported that minority and ethnic groups are being diagnosed with colorectal cancer at younger ages and more advanced stages than non-Hispanic whites. The study was recently published in Cancer Medicine.1 “While we know the risk of...
Myeloablative Conditioning for Stem Cell Transplantation Remains Standard of Care in Patients With MDS and AML
A randomized trial from the Bone and Marrow Transplant Clinical Trials Network was halted early after concluding that allogeneic stem cell transplantation after a reduced-intensity conditioning regimen resulted in higher relapse rates compared to myeloablative conditioning. The phase III randomized ...
New Use for CAR-T Cells Post Transplantation
The approach of using genetically engineered chimeric antigen receptor (CAR)-T cells has received much attention for treating leukemias, where it has achieved spectacular long-lasting complete remissions in some patients with no other treatment options. CAR-T cells are also being studied in...
Expert Point of View: Kanti Rai, MD
In a separate interview, Kanti Rai, MD, of the Northwell Health System in New Hyde Park, New York, noted that venetoclax is one of several “exciting recent developments in this disease.” There is the Bruton tyrosine kinase inhibitor ibrutinib (Imbruvica), the PI3K inhibitor idelalisib (Zydelig),...
Venetoclax May Prove to Be Strong Weapon Against Poor-Prognosis Chronic Lymphocytic Leukemia
Venetoclax, the latest entry into the field of treatment of chronic lymphocytic leukemia (CLL), is a powerful investigational therapy that promises to fill an important niche: treatment of high-risk relapsed/refractory patients with deletions of 17p. Nearly 80% of patients with relapsed/refractory...
Severe Toxicities Seen in Younger Patients Receiving Front-Line Idelalisib for Chronic Lymphocytic Leukemia
Hematologists and patients with chronic lymphocytic leukemia (CLL) are excited about new drugs that have dramatically improved outcomes. But all drugs have side effects, and it is important to be aware of potential consequences. Hepatotoxicity turns out to be a major concern in younger CLL patients ...
Idelalisib Improves Progression-Free Survival Over Bendamustine Plus Rituximab in Chronic Lymphocytic Leukemia
Idelalisib (Zydelig) combined with bendamustine (Bendeka, Treanda) plus rituximab (Rituxan) was superior to chemotherapy with bendamustine/rituximab plus placebo, reducing the risk of progressive disease and death while improving progression-free survival and overall survival in patients with...
Expert Point of View: Robert Hromas, MD, and Timothy A. Graubert, MD
Robert Hromas, MD, of the University of Florida College of Medicine, Gainesville, who moderated a press briefing, commented that the finding of benefit with rituximab “resolves a long-standing controversy” with this cancer. “These results are exciting for those of us who treat leukemia,” he...
Rituximab Adds Benefit to Chemotherapy in Adult B-Cell Precursor ALL
The addition of rituximab (Rituxan) to the pediatric-inspired chemotherapy protocol for B-cell precursor acute lymphoblastic leukemia (ALL) significantly improved event-free survival in a large European study presented at the 2015 ASH Annual Meeting.1 The GRAALL-R 2005 phase III study is the first...
ALK Rearrangements Common in Young Patients With Lung Cancer
Two investigative groups have reported interesting observations about genomic alterations in the tumors of young patients with lung cancer. Notably, ALK rearrangement was the most common driver mutation found, in studies reported at the 16th World Conference on Lung Cancer.1,2 “To our knowledge,...
Patient-Centric Care: Translating Research to Results
The 2016 Genitourinary Cancers Symposium was held earlier this month in San Francisco. Abstracts and presentations included data and discussion on the latest strategies in the prevention, screening, diagnosis, and treatment of prostate, kidney, testicular, and urothelial cancers. Snapshots of data...
Elotuzumab in Previously Treated Multiple Myeloma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On November 30, 2015, elotuzumab (Empliciti) was approved for...
Ado-Trastuzumab Emtansine Improved Overall Survival for Heavily Pretreated Patients With HER2-Positive Breast Cancer
Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy (trastuzumab [Herceptin] and lapatinib [Tykerb]), median overall survival was increased for those treated with ado-trastuzumab emtansine (aka T-DM1...
Plasma-Based Test Identifies Impactful Mutations in BOLERO-2 Population
A plasma-based cell-free DNA test identified mutations in the estrogen receptor 1 gene (ESR1) in 30% of patients from the BOLERO-2 trial of everolimus (Afinitor) plus exemestane, and these mutations were correlated with survival. The results, which support the use of plasma as a source of...
Neoadjuvant Palbociclib Enhances Effect of Anastrozole on Complete Cell-Cycle Arrest
The cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib (Ibrance) enhanced cell-cycle control over that achieved with anastrozole alone in a study that evaluated the drugs’ ability to induce complete cell-cycle arrest in tumor cells and to produce clinical responses, as neoadjuvant therapy for ...
Could CAR-T Therapy Be Moving Into Lymphoma?
The use of T cells that are genetically engineered to express chimeric antigen receptor (CAR-T) has made headway as an approach to hematologic malignancies, with the best results achieved in leukemia. At the 2015 American Society of Hematology (ASH) Annual Meeting and Exposition, a preliminary...
Expert Point of View: Paul Bunn, Jr, MD
Although the results for E1505 were negative, “overall survival and disease-free survival are not the only things we can learn from this trial,” said Paul Bunn, Jr, MD, Distinguished Professor in the Division of Medical Oncology at the University of Colorado, Denver, who formally discussed the...
Multiple Myeloma in 2015: A Year for the Record Books
Few malignancies have received as much attention, in the way of newly approved drugs, as multiple myeloma did in 2015. In November alone, 3 new agents were approved, bringing the total to 4 for the year as part of a record 7 approvals and to 16 regulatory approvals over the past 12 years. Speakers...
Study Finds Alectinib Highly Active in ALK-Positive, Crizotinib-Resistant NSCLC
In a North American phase II trial reported in The Lancet Oncology, Shaw et al found that alectinib (Alecensa), which is active against acquired crizotinib (Xalkori) resistance mutations and exhibits high central nervous system (CNS) penetration, was associated with considerable activity in...
Swedish Study Indicates No Pregnancy-Related Increase in Risk of Relapse in Hodgkin Lymphoma
In a Swedish study reported in the Journal of Clinical Oncology, Weibull et al found that pregnancy did not appear to increase the risk of subsequent relapse in women with Hodgkin lymphoma in remission. Study Details The study included data from Swedish health-care registers and medical records...
